Ten years after Pfizer Inc. voluntarily yanked it from the market due to toxicity issues, acute myeloid leukemia (AML) drug Mylotarg (gemtuzumab ozogamicin) is returning to the market, following FDA approval Friday for use in adults with newly diagnosed disease whose tumors express the CD33 antigen.